ELICIO THERAPEUTICS INC (ELTX:NASDAQ)
$2.76 -1.32 (-32.3529%)
Analysed ELICIO THERAPEUTICS INC (ELTX:NASDAQ) News Sources
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
15-06-2026
yahoo.com
Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX)
15-06-2026
advfn.com
Stocks Soar on US-Iran Peace Agreement
15-06-2026
barchart.com
Stocks Rally as US-Iran Peace Deal Sinks Oil and Bond Yields
15-06-2026
barchart.com
Sector Update: Healthcare Stocks Softer Monday Afternoon
15-06-2026
yahoo.com
Top Midday Decliners
15-06-2026
yahoo.com
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints
15-06-2026
stocktwits.com
Sector Update: Healthcare Stocks Softer Late Afternoon
15-06-2026
yahoo.com
Stocks Settle Sharply Higher as US-Iran Peace Deal Spurs Optimism
15-06-2026
barchart.com
This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation
16-06-2026
barchart.com
What is the current price of ELICIO THERAPEUTICS INC (ELTX:NASDAQ)?
The current price of ELICIO THERAPEUTICS INC (ELTX:NASDAQ) is $2.76.
ELICIO THERAPEUTICS INC (ELTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of ELICIO THERAPEUTICS INC (ELTX:NASDAQ) since the previous trading day is $-1.32.
ELICIO THERAPEUTICS INC (ELTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of ELICIO THERAPEUTICS INC (ELTX:NASDAQ) since the previous trading day is -32.3529%.
What is the most recent average sentiment score for ELICIO THERAPEUTICS INC (ELTX:NASDAQ)?
The most recent average sentiment score for ELICIO THERAPEUTICS INC (ELTX:NASDAQ) is 53 out of 100.
What is the most recent average sentiment for ELICIO THERAPEUTICS INC (ELTX:NASDAQ)?
The most recent sentiment for ELICIO THERAPEUTICS INC (ELTX:NASDAQ) is .
SEC-8K** Filing Available For ELICIO THERAPEUTICS INC (ELTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.